Thomas Sorz-Nechay

Thomas Sorz-Nechay

Auto-generated profile, based on publicly available information

Thomas Sorz-Nechay

Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in JHEP Reports
Verified
Journal Article
Open access
LŽLaura Žigutytė
Laura Žigutytė
TSThomas Sorz-Nechay
Thomas Sorz-Nechay
JCJan Clusmann
Jan Clusmann
JKJakob Nikolas Kather
Jakob Nikolas Kather
Artificial intelligence (AI) methods enable humans to analyse large amounts of data, which would otherwise not be feasibly quantifiable. This is especially true for unstructured visual and textual data, which can contain invaluable insights into disease. The hepatology research landscape is complex and has generated large amounts of data to be mined. Many open questions can potentially be addressed with existing data through AI methods. However, the field of AI is sometimes obscured by hype cycles and imprecise terminologies. This can conceal the fact that numerous hepatology research groups already use AI methods in their scientific studies. In this review article, we aim to assess the contemporaneous use of AI methods in hepatology in Europe. To achieve this, we systematically surveyed all scientific contributions presented at the EASL Congress 2024. Out of 1,857 accepted abstracts (1,712 posters and 145 oral presentations), 6 presentations (∼4%) and 69 posters (∼4%) utilised AI methods. Of these, 55 posters were included in this review, while the others were excluded due to missing posters or incomplete methodologies. Finally, we summarise current academic trends in the use of AI methods and outline future directions, providing guidance for scientific stakeholders in the field of hepatology.

5 October 2021 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
DPDavid Pereyra
David Pereyra
SHStefan Heber
Stefan Heber
WSWaltraud C. Schrottmaier
Waltraud C. Schrottmaier
JSJonas Santol
Jonas Santol
APAnita Pirabe
Anita Pirabe
Alice AssingerAlice Assinger
Alice Assinger
Anticoagulation was associated with improved survival of hospitalized coronavirus disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-associated coagulopathy (CAC) and the mechanism responsible for improved survival of anticoagulated patients with COVID-19 remain largely elusive. This investigation aimed to explore the effects of anticoagulation and low-molecular-weight heparin (LMWH) in particular on patient outcome, CAC development, thromboinflammation, cell death, and viral persistence. Data of 586 hospitalized COVID-19 patients from three different regions of Austria were evaluated retrospectively. Of these, 419 (71.5%) patients received LMWH and 62 (10.5%) received non-vitamin-K oral anticoagulants (NOACs) during hospitalization. Plasma was collected at different time points in a subset of 106 patients in order to evaluate markers of thromboinflammation (H3Cit-DNA) and the cell death marker cell-free DNA (cfDNA). Use of LMWH was associated with improved survival upon multivariable Cox regression (hazard ratio = 0.561, 95% confidence interval: 0.348–0.906). Interestingly, neither LMWH nor NOAC was associated with attenuation of D-dimer increase over time, or thromboinflammation. In contrast, anticoagulation was associated with a decrease in cfDNA during hospitalization, and curtailed viral persistence was observed in patients using LMWH leading to a 4-day reduction of virus positivity upon quantitative polymerase chain reaction [13 (interquartile range: 6–24) vs. 9 (interquartile range: 5–16) days, P = 0.009]. Time courses of haemostatic and thromboinflammatory biomarkers were similar in patients with and without LMWH, indicating either no effects of LMWH on haemostasis or that LMWH reduced hypercoagulability to levels of patients without LMWH. Nonetheless, anticoagulation with LMWH was associated with reduced mortality, improved markers of cell death, and curtailed viral persistence, indicating potential beneficial effects of LMWH beyond haemostasis, which encourages use of LMWH in COVID-19 patients without contraindications.

22 January 2026 in Journal of Hepatology
Verified
Journal Article
Open access
BHBenedikt Silvester Hofer
Benedikt Silvester Hofer
MTMarta Tonon
Marta Tonon
LBLaura Buttler
Laura Buttler
JNJoana Camões Neves
Joana Camões Neves
QHQueralt Herms
Queralt Herms
AAAgustín Albillos
Agustín Albillos
Alcohol abstinence enables hepatic recompensation in patients with decompensated alcohol-related cirrhosis. This study investigated the incidence, predictors, and impact of abstinence-induced recompensation. This multicentre study included patients with decompensated alcohol-related cirrhosis recruited at the time of abstinence up to December 2022. Recompensation was defined by Baveno VII criteria: (i) sustained abstinence (≥3 months), (ii) resolution of ascites and hepatic encephalopathy off therapy, (iii) absence of variceal bleeding for 1 year, and (iv) restored liver function (Child-Pugh A or MELD <10). A total of 633 patients from 17 centres were included (71.7% male; median age 55 years). Alcohol-associated hepatitis superimposed on cirrhosis was present in 40.8%. Median MELD was 19 (13-24), and 47.2% had progressed to further decompensation at abstinence. Median time from index decompensation to abstinence was 0.2 (0.0-7.6) months. Over a follow-up of 36.3 (19.2-63.2) months, 197 patients (31.1%) achieved recompensation (cumulative incidence: 12.3% at 1 year, 23.4% at 2 years, 33.8% at 5 years). Early abstinence (within 1 month of decompensation; adjusted subdistribution hazard ratio [aSHR] 2.042), higher aspartate aminotransferase (aSHR per 10 U/L increase: 1.011) and gamma-glutamyltransferase (aSHR per 10 U/L increase: 1.004) (all p <0.001) increased recompensation likelihood in both supervised and machine-learning models, while the presence of further decompensation decreased it (aSHR 0.650, p = 0.013). During follow-up, 123 patients died (56.1% liver-related). Recompensation was independently associated with lower all-cause mortality (aHR 0.255, p = 0.001). No recompensated patient who remained abstinent died of liver-related causes or developed hepatocellular carcinoma. Alcohol abstinence enabled hepatic recompensation in approximately one-third of patients with decompensated alcohol-related cirrhosis, particularly when abstinence was achieved early and in the absence of further decompensation. Recompensation was associated with a substantial survival benefit under sustained abstinence, with a negligible residual risk of liver-related death and hepatocellular carcinoma. Hepatic recompensation, as defined by Baveno VII, is a novel clinical concept reflecting the potential for disease regression and resolution of decompensating events in patients with cirrhosis once the underlying aetiological factor is removed or controlled. In this multicentre study, sustained alcohol abstinence led to recompensation in one-third of patients with decompensated alcohol-related cirrhosis within 5 years, particularly if abstinence was achieved early and in the absence of further decompensation. Recompensation markedly improved outcomes, with a negligible residual risk of liver-related death and hepatocellular carcinoma when abstinence was maintained. These findings support personalised treatment approaches in decompensated alcohol-related cirrhosis by enabling the identification of patients at risk of progression or with the potential for regression.

29 September 2024 in Digestive and Liver Disease
Verified
Journal Article
Open access
BHBenedikt Silvester Hofer
Benedikt Silvester Hofer
BSBenedikt Simbrunner
Benedikt Simbrunner
PKPhilipp Königshofer
Philipp Königshofer
KBKsenia Brusilovskaya
Ksenia Brusilovskaya
OPOleksandr Petrenko
Oleksandr Petrenko
TRThomas Reiberger
Thomas Reiberger
Cirrhosis is associated with a proinflammatory environment. To analyse aetiology-specific inflammation patterns in compensated cirrhosis in animal models and patients. Portal pressure (PP), fibrosis (collagen proportionate area [CPA]) and hepatic inflammation were measured in cirrhotic rat models (thioacetamide [TAA;n = 12]; choline-deficient high-fat diet [CDHFD;n = 12]; bile duct ligation [BDL;n = 16]). Compensated cirrhotic patients (alcohol-related liver disease [ALD;n = 67]; metabolic dysfunction-associated steatohepatitis [MASH;n = 50]; cholestatic liver disease [primary biliary cholangitis [PBC]/primary sclerosing cholangitis [PSC];n = 22]) undergoing hepatic venous pressure gradient (HVPG) measurement were included. In rats, hepatic proinflammatory gene expression was highest in CDHFD and lowest in TAA, despite comparable PP levels. Across all animal models, Tnfa/Il6 correlated positively with CPA, and Mcp1 with elevated PP. Mcp1 was also associated with increased CPA in TAA/CDHFD. Mcp1/Cxcl1 showed a model-independent positive correlation to transaminases. Il1b correlated positively with CPA/PP in BDL and with transaminases in CDHFD. In patients, CRP/IL-6 were lower in MASH compared to ALD or PBC/PSC, regardless of hepatic function. IgA/IgG were highest and complement factors lowest in ALD. More pronounced systemic inflammation was linked to higher HVPG primarily in ALD/MASH. Proinflammatory pathways are upregulated across all liver disease aetiologies, yet their association with fibrosis and portal hypertension can vary.

17 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
OPOleksandr Petrenko
Oleksandr Petrenko
TSThomas Sorz-Nechay
Thomas Sorz-Nechay
MBMartin Bilban
Martin Bilban
SDSophia Derdak
Sophia Derdak
LMLukas Van Melkebeke
Lukas Van Melkebeke
THTim Hendrikx
Tim Hendrikx
Alcohol-related liver disease (ALD) remains a major global health burden with limited therapeutic options due to an incomplete understanding of its underlying molecular mechanisms and cellular crosstalk. Here, we applied ultra-high resolution (on 2 µm spots) spatial transcriptomics to a cirrhotic liver tissue obtained from an end-stage ALD patient, analyzing >265,000 spatially resolved cells with further validation on single-cell and single-nuclei datasets from patients with ALD cirrhosis. Our analysis delineated distinct cellular sub-populations and molecular landscapes across fibrotic, vascular, and parenchymal niches of ALD cirrhosis. We identified robust zonation of hepatocytes, hepatic stellate cells, and diverse immune subpopulations, including enrichment of pro-inflammatory T cells and dendritic cells in the fibrotic niche and MARCO + tissue-resident macrophages localizing mostly in parenchymal areas. Analysis of spatial metrics assigned expression of WNT4, RCAN3, PPIAL4G, PLA2G5 , and SLC6A9 to the fibrotic environment in ALD. Differential expression and ligand–receptor interactome analyses revealed niche-specific signaling, with marked CCL19 – CCR7 activity in fibrotic regions and DLL4 – NOTCH3 crosstalk in vascular compartments. Notably, WNT4 + fibroblasts emerged as key mediators of extracellular matrix remodeling and chemoattraction, particularly via CCL19-mediated signaling towards CD8 + T cells, which was validated on single-cell resolution within the ALD cirrhotic liver in external datasets. These spatial and single-cell findings highlight novel potential therapeutic targets for patients with ALD cirrhosis.

14 June 2026 in Scientific Reports
Verified
Journal Article
Open access
PKPhilipp Königshofer
Philipp Königshofer
KBKsenia Brusilovskaya
Ksenia Brusilovskaya
BHBenedikt Silvester Hofer
Benedikt Silvester Hofer
OPOleksandr Petrenko
Oleksandr Petrenko
BSBenedikt Simbrunner
Benedikt Simbrunner
TRThomas Reiberger
Thomas Reiberger
Characterization of toxin-induced mouse models of regressive liver disease, focusing on the detecting of a suitable therapeutic window during fibrosis and portal hypertension (PH) regression. C57BL/6JRj mice were studied when exposed to thioacetamide (TAA) or carbon tetrachloride (CCl4) for 8 or 12 weeks (8w/12w) and after one/two (+R1/+R2) week(s) of TAA/CCl4-free regression. Healthy controls received NaCl or olive oil (OO). Primary readouts included liver fibrosis (collagen proportionate area, CPA), portal pressure (PP), serum transaminases and hepatic fibrosis-related gene expression. The diseased models (8wTAA/12wTAA/8wCCl4/12wCCl4) showed significant fibrosis (CPA: 3.03/3.87/8.53/16.90%; vs. NaCl/OO: 0.87/1.15%) and PH (PP: 6.8/7.7/8.5/10.0 mmHg; vs. NaCl/OO: 5.5/5.1 mmHg). CPA significantly regressed in 8wTAA+R1 (2.60%; p = 0.01) and 12wCCl4+R1 (10.9%; p = 0.01), but not in 12wTAA+R1/8wCCl4+R1. CPA regression was significant in all +R2-groups (p < 0.001) but not in 8wCCl4+R2 (p = 0.30). Significant PP regression was found at 8wCCl4+R1 (5.8 mmHg; p = 0.004) and 12wCCl4+R1 (8.4 mmHg; p = 0.01), but not in the 8w/12w TAA models. All +R2-groups showed significant PP regression: 8wTAA+R2 (6.0 mmHg; p ≤ 0.001), 12wTAA+R2 (6.0 mmHg), 8wCCl4+R2 (6.0 mmHg, p = 0.004) and 12wCCl4+R2 (7.9 mmHg, p = 0.008). Serum AST/ALT levels at +R1/+R2 returned to levels of healthy controls. Hepatic Col1a1 and Timp1 gene expression peaked in 12w-groups and showed a gradual decrease at +R1/+R2: Col1a1 (12wTAA+R1/+R2: -14%/-29%, p = 0.002; 12wCCl4+R1/R2: -28%/-23%, p = 0.05) and Timp1 (12wTAA+R1/+R2: -41%/-61%, p ≤ 0.001; 12wCCl4+R1/R2: -43%/-40%, p ≤ 0.001). While liver disease regressed in all models/timepoints, both liver fibrosis (CPA) and PP remained increased in the 12wCCl4+R1/R2 settings - qualifying this model as suitable for pre-clinical testing of therapeutic strategies aimed at promoting liver fibrosis and PH regression.